NCT00002098View on ClinicalTrials.gov

Phase I/II Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

Not specified

Conditions
HIV Infections
Interventions
DRUG

Lentinan

DRUG

Didanosine

Trial Locations (2)

32751

Goodgame Med Group, Maitland

94109

ViRx Inc, San Francisco

Sponsors

Lead Sponsor

AJI Pharma USA
All Listed Sponsors
lead

AJI Pharma USA

INDUSTRY

NCT00002098 - Phase I/II Study of the Tolerance and Efficacy of Combined Use of Didanosine (2',3'-Dideoxyinosine; ddI) and Lentinan in HIV-Positive Patients | Biotech Hunter | Biotech Hunter